<?xml version="1.0" encoding="UTF-8"?>
<p>Compliance with GMP standards has been a major challenge for the progress of ATMP in Europe. In fact, these difficulties are a primary reason why, till 2014, only four drugs, under the ATMP regulation, were authorized through the centralized EU drug licensing process [
 <xref rid="R16" ref-type="bibr">16</xref>]. For this reason, the EC has developed a 2-year program under FP7 with the acronym AGORA [
 <xref rid="R17" ref-type="bibr">17</xref>] (ATMP GMP Open Access Research Alliance) coordinated by the UK and designed to create a source of information to support biomedical and clinical research through a platform. This platform facilitates the consultation among researchers working in the field, as well as support for ATMPs academic programmers to comply with legislation, while promoting the development of early-stage therapies to commercial trials.
</p>
